There is a renewed interest in rare disease research driven by advances in molecular biology as well as regulatory incentives in the United States and Europe. Here, Dr. Cynthia Jackson, vice president and head of the Pediatric Center of Excellence, explains why these factors are contributing to a bright future for rare disease clinical research.